HSPA5 and neoplasm: At day 34 post‐treatment initiation, BLI imaging revealed that the group of tumor‐bearing mice treated with the targeted RGD4C/AAVP‐Grp78‐HSVtk plus GCV had smaller tumors with lower viability as shown by the total Luc signals in tumors, compared to the large size and highly viable tumors from mice receiving the control non‐targeted vector and GCV (Fig 9B and C).